Founded in 2017, Origincell is a manufacturer and marketer of automatic cryogenic equipment to freeze and low-temperature storage of biological, genomic, and diagnostic samples.
Origincell (Chinese: 原能生物) raised CNY 410 million (USD 62 million) in a Series A financing round. The existing shareholder Canature (Chinese: 开能健康, 300272), Deluxe Family (Chinese: 华丽家族, 600503), Gaosen Funds (Chinese: 高森系列基金) and employee stock ownership platform continued investment. The founder and chairman of the company, Mr. Qu Jianguo, and Lishui Gaosen Fund have followed the investment.
The fund will be used to build the self-owned intelligent manufacturing base to meet the scale-up and development needs. As well as continue to upgrade the automatic cryogenic biological sample storage equipment, global sales channel distribution, service network construction and vertical M&A.
The development of translational medicine, precision medicine, and big data has promoted the demand for biological samples and accelerated the establishment of biobanks.
As the upstream supplier of biobanks, the global biomedical cryogenic storage market is expected to reach USD 3.65 billion in 2025, with an average annual compound growth rate of 4.13%. China’s market is expected to reach USD 207 million in 2025, with an average annual compound growth rate of 5.22%, according to Global Market Insights.
Origincell’s competitors include Haier-Medical (Chinese: 海尔生物, 688139. SH), AUCMA (Chinese: 澳柯玛, 600336. SH) and Meling (Chinese: 美菱生物医疗, 835892. OC)